BioSpace News Archive

In Vitro Diagnostics Market Size to Reach US$ 106,914.16 Mn by 2030

The global in vitro diagnostics market was valued at $71,496.16 million in 2020, and is projected to reach US$ 106,914.16 million by 2030, growing at a CAGR of 4.08% from 2021 to 2030.

May 20, 2022
·
9 min read
Biotech Bay

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - May 20, 2022

Iovance Biotherapeutics, Inc. announced that on May 19, 2022, the Company approved the grant of inducement stock options covering an aggregate of 146,700 shares of Iovance’s common stock to 17 new non-executive employees.

May 20, 2022
·
5 min read
Pharm Country

Viatris to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference

Viatris Inc., a global pharmaceutical company, announced the company will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, CA on Tuesday, June 14, 2022.

May 20, 2022
·
1 min read
Pharm Country

Taro to Announce Full Year Results on May 26, 2022

Taro Pharmaceutical Industries Ltd. announced that it plans to release its financial results for the year ended March 31, 2022, after the close of market on Thursday, May 26, 2022.

May 20, 2022
·
1 min read
Biotech Beach

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 21, 2022

Arcturus Therapeutics Holdings Inc. announced that the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 38,800 shares of Arcturus common stock to five newly-hired employees.

May 20, 2022
·
4 min read
BioCapital

Statement of Forest Service Chief Randy Moore Announcing Pause of Prescribed Fire Operations on National Forest System Lands

Today, because of the current extreme wildfire risk conditions in the field, I am initiating a pause on prescribed fire operations on National Forest System lands while we conduct a 90-day review of protocols, decision support tools and practices ahead of planned operations this fall.

May 20, 2022
·
2 min read
FDA

AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of Advanced Parkinson’s Disease

AbbVie (NYSE: ABBV) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in patients with advanced Parkinson’s disease (PD).

May 20, 2022
·
9 min read